APA (7th ed.) Citation

López-Guillermo, A., Canales, M. Á., Dlouhy, I., Mercadal, S., Briones, J., Martín García-Sancho, A., . . . Conde, E. (2022). A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. Leukemia & Lymphoma, 63(1), 93. https://doi.org/10.1080/10428194.2021.1971216

Chicago Style (17th ed.) Citation

López-Guillermo, Armando, et al. "A Randomized Phase II Study Comparing Consolidation with a Single Dose of 90Y Ibritumomab Tiuxetan Vs. Maintenance with Rituximab for Two Years in Patients with Newly Diagnosed Follicular Lymphoma Responding to R-CHOP. Long-term Follow-up Results." Leukemia & Lymphoma 63, no. 1 (2022): 93. https://doi.org/10.1080/10428194.2021.1971216.

MLA (9th ed.) Citation

López-Guillermo, Armando, et al. "A Randomized Phase II Study Comparing Consolidation with a Single Dose of 90Y Ibritumomab Tiuxetan Vs. Maintenance with Rituximab for Two Years in Patients with Newly Diagnosed Follicular Lymphoma Responding to R-CHOP. Long-term Follow-up Results." Leukemia & Lymphoma, vol. 63, no. 1, 2022, p. 93, https://doi.org/10.1080/10428194.2021.1971216.